Dive into our GLP-1 resource center for stories on weight loss, medications, side effects, and more
Enhanced Metabolic Health Users notice improvements in various metabolic markers, including blood sugar, blood pressure, and cholesterol, ultimately reducing inflammation
Lillys oral drug orforglipron was discovered by Japanese company Chugai Pharmaceuticals and licensed to Lilly in 2018
N Engl J Med 345(12):861869 Moorhead JF, Brunton C, Varghese Z (1997) Glomerular atherosclerosis
Although the SAVOR and EXAMINE studies were delineated to verify cardiovascular safety of two DPP-4i, namely saxagliptin and alogliptin, respectively, both are considered to be the first controlled clinical trials to address the effect of GLP-1 system on CVD
Real-world data analyses revealed a substantial increase in the prevalence of CKM-related componentsincluding type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, and obesitybetween 2020 and 2022, with the prevalence of prediabetes rising by as much as 170% [12]